DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2015/0133469 A1 O'garra Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2015/0133469 A1 O'garra Et Al US 2015O133469A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0133469 A1 O'Garra et al. (43) Pub. Date: May 14, 2015 (54) EARLY DETECTION OF TUBERCULOSIS Related U.S. Application Data TREATMENT RESPONSE (60) Provisional application No. 61/610,121, filed on Mar. (71) Applicants: BAYLOR RESEARCH INSTITUTE, 13, 2012. Dallas, TX (US); MEDICAL RESEARCH COUNCIL, Swindon Publication Classification (GB); IMPERIAL COLLEGE (51) Int. Cl. HETICARE NHS TRUST, London CI2O I/68 (2006.01) A63L/33 (2006.01) (72) Inventors: Anne O'Garra, London (GB); Chloe st 7. :08: Bloom, London (GB); Matthew Paul A613 L/4965 (2006.015 Reddoch Berry, London (GB); Robert Wilkinson, Observatory (ZA); Jacques (52) U.S. Cl. F. Banchereau, Montclair, NJ (US); CPC ............ CI2O I/6883 (2013.01); A61 K3I/496 Damien Chaussabel, Bainbridge Island, (2013.01); A61 K3I/4965 (2013.01); A61 K WA (US); Maria Virginia Pascual, 31/455 (2013.01); A61K 31/133 (2013.01); Dallas, TX (US) C12O 2600/158 (2013.01); C12O 2600/I 18 (2013.01) (21) Appl. No.: 14/384,891 (57) ABSTRACT (22) PCT Filed: Mar. 13, 2013 The present invention includes methods for early detection of a treatment response in a patient Suspected of being infected (86). PCT No.: PCT/US2O13/030986 with Mycobacterium tuberculosis. Changes in the blood tran S371 (c)(1), scriptome are detectable within two weeks of the initiation of (2) Date: Sep. 12, 2014 antituberculosis therapy. Patent Application Publication May 14, 2015 Sheet 1 of 66 US 201S/O133469 A1 Fig. A South Africa Active 3 airiers irst Critisetia later Batis is ricsi criteria: Cultire: icositive pirnorary is i{GFA --ye, clirically we fe ya Age years Age > if years a "ser for 1.2 traits Š S S XXX & & P-38 Sangie Carrrk:ced Bri-Estreater No evidence of active is at 2 months 2 weeks. Sarpie S excided: 8 Yissed a Sarnate, i poor quairy contro Patent Application Publication May 14, 2015 Sheet 2 of 66 US 201S/O133469 A1 Fig, 1.8 Eik 8 active 8 patients inclusion criteria As above: Cirica review 23 nonths Connented atti-B treatneri 2 weeks sangle 2 months sainie 4 norths sain pie 6 norths sample Patent Application Publication May 14, 2015 Sheet 3 of 66 US 201S/O133469 A1 SSE SLR.S.E Patent Application Publication US 201S/O133469 A1 QZ(344 Patent Application Publication May 14, 2015 Sheet 5 of 66 US 201S/O133469 A1 IFI Sigilaling Pathay Extracellular Space Cytoplasin f-extreSSed ticleIS 6. Sp652FKB ASVYaaper\Sir A\S><g S. Bak - if PSA?iB3 F.35 (i. Patent Application Publication May 14, 2015 Sheet 6 of 66 US 201S/O133469 A1 Fig 23 at 2 JAK CPIP - - - - GiliCOCOrticoid Patent Application Publication May 14, 2015 Sheet 7 of 66 US 201S/O133469 A1 Fig. 2E Treated South Africa 30 Coort fissatist 388- P-as xerox S 8.8. a8ar | s Fig. 2F Treated Soisi africa 20 i (aiyar f$84 iss aska SSS S. Patent Application Publication US 201S/O133469 A1 Patent Application Publication May 14, 2015 Sheet 9 of 66 US 201S/O133469 A1 ????? - Patent Application Publication May 14, 2015 Sheet 10 of 66 US 201S/O133469 A1 Fig. 3C Active TB Training Set (39 is S. Fig. 3D Active TB Test Set (391 fist S: Patent Application Publication May 14, 2015 Sheet 11 of 66 US 201S/O133469 A1 Fig. 3E irectfrieff Specific Signature f39; ist: stegulated & Pl: charge & Jpregulated ill Eiserlap...ith data:st 8: -kgiE-Hip-salu Eos cissisir Rs.8gitis iscstas i: Exogiorgi B3;is is sid.iises Ex: ci Missix.iisgas. Fixssists & Exc3:Eis a: if R:listois & hiri, m m m m m m mm mm m m 333 TRE a sigrating 3:::::itical Risesistiar & LEristic & see irists if: scists: firsts six sons:rkrit Systasy S ea left Signature 38i is Patent Application Publication May 14, 2015 Sheet 12 of 66 US 201S/O133469 A1 % ???? Patent Application Publication US 201S/O133469 A1 42 ||sipuoluzi 427 429 |suluotu9 it. Patent Application Publication May 14, 2015 Sheet 14 of 66 US 201S/O133469 A1 Active TB Training Set (391 list -32 43. HSuluotuz ||Sunuou9 |suuouzi 38 s |sipuoluz |sinuou9 Patent Application Publication May 14, 2015 Sheet 15 of 66 US 201S/O133469 A1 Fig. 5A Change in featre at Specific Signature is Waitiates As rises entiet K Csert treated 2 wks. 2 int. a "?t 6th Fig. 5R : 8: Patent Application Publication May 14, 2015 Sheet 16 of 66 US 201S/O133469 A1 2004 2009 ºsºsocos <><i><s N |sutuou9 |sipuolup 265 2074 evsºsocose ? ºsºsocos <S<><ses |sinuouz Patent Application Publication May 14, 2015 Sheet 18 of 66 US 201S/O133469 A1 The Changing transcriptional Response is independent of the lagnitude of the Untreated Transcriptional Signature Ireated South Africa 2011 Cohort (664 ist) O : 80 S to . 60 ------2 ?eekS SS - E - 2 riffis SS 40 --A-6 months -- 12 months S 20 0 2. 40 600 800 Weighted Molecular isiance it fai fi. Patent Application Publication May 14, 2015 Sheet 19 of 66 US 201S/O133469 A1 ;&&***** % @: Patent Application Publication May 14, 2015 Sheet 20 of 66 US 201S/O133469 A1 Active TB Test Set (391) 413 jerodiligt asuodsæ8Jejmo?jow |suuouzi if 42 41 • «N• sor |suuouzi F. fi Patent Application Publication May 14, 2015 Sheet 21 of 66 US 201S/O133469 A1 Active TB Test Set (391) 42 i3S ^<+socos • ousºseco • / (Cont'd) Patent Application Publication May 14, 2015 Sheet 22 of 66 US 201S/O133469 A1 Fig. 8A The Barry et at 383 & 83 Active 8 Signatures Significantiy finitish in Response to Sticcessfai Treatnet in She South Africa. 3... Cahort 333 Sisingiture Nitri Yaise expression +3. SS Š treated r as frth 12 ninth 86 signatire Naiss: expression treated Sint Patent Application Publication May 14, 2015 Sheet 23 of 66 US 201S/O133469 A1 Fig. 8B 393 sigraiurg crasse exissio? 86 signitia raise &Xg &Ssign st2.4 Patent Application Publication May 14, 2015 Sheet 24 of 66 US 201S/O133469 A1 Fig. 8C 333 signitie 85 signati & 8 k 88: s s is Sir SS a s is: S- s s Fig. 9 Siricisio: Cfit Cuit repositive pimonary 8 Active TB GRAve., c. icaity weii B} --vis fry Age > 3 years Age Y i8 years rica awaii for 2 norths {in a resies in 12 ri?inths ŠS S S SSS S SS S. N. Š S S. SS SyS, is excide. not fif inclusioi crite fia 13 saw articists SSSS SS S. SS Š S. S SSSX S. S Patent Application Publication May 14, 2015 Sheet 25 of 66 US 201S/O133469 A1 Patent Application Publication May 14, 2015 Sheet 26 of 66 US 201S/O133469 A1 Patent Application Publication May 14, 2015 Sheet 27 of 66 US 201S/O133469 A1 IPA of 565 transcripts feated South Africa 2011 Chart 0. {3: 20 issis 40an 9.SS 60 is3 80 iiiraiei is c\ s s pilify E. AEI E Fi, f. (Conid Patent Application Publication May 14, 2015 Sheet 28 of 66 US 201S/O133469 A1 Patent Application Publication May 14, 2015 Sheet 29 of 66 US 201S/O133469 A1 Patent Application Publication May 14, 2015 Sheet 30 of 66 US 201S/O133469 A1 IPA of 224 transcripts Ireated South Africa 2011 Coiffi 3. - S. SS3, . 40 SSs 60. - S 80 to Untreated t YY: i liteited S. s. s. s s : Plji AAFY is Affif. Fi, ii. (Conid Patent Application Publication May 14, 2015 Sheet 31 of 66 US 201S/O133469 A1 Š SS S Patent Application Publication May 14, 2015 Sheet 32 of 66 US 201S/O133469 A1 §6º0'?gº08ºgog9101 Patent Application Publication May 14, 2015 Sheet 33 of 66 US 201S/O133469 A1 IPA of 711 transcripts icated Stiff Africa 2011 Citri O : 20 -Sg S. 40 SS 60 S 80 iO opw ss. 5 S is filiff ARY FE LAf F. C. (Conti) Patent Application Publication May 14, 2015 Sheet 34 of 66 US 201S/O133469 A1 Fig. 10D 28S Coiffs Kiraining 565 si SA 2. list Fig. 10E SA 2). 2G9 & 2Ci: Cohorts featre it Sigitatre SA 23 Active 8 Signate 2GOS Coorts twe: tapping Weri frar scripts 344 trafscripts Patent Application Publication May 14, 2015 Sheet 35 of 66 US 201S/O133469 A1 Fig. A ketiye Egates.iciusior triteria: latest8tists inclusion crite:ia: {Cite positives to stry $8 {{SRA is, tiricaity wei 8w ye - : W sys Rge x 3 year's Age x 3 yea:S Citics risik is 3 tists {Bica fissists or raisits 38-traits:: &3 Spies i: sats: Sagi. hia &ireita Rative 3 at is fiants 2 : sixtis: 88:8 8:3this six frie S S 2 orths sspie SSSSSSSSS SS S Š SSSSSSSSSSS O Š SS SS S. Patent Application Publication May 14, 2015 Sheet 36 of 66 US 201S/O133469 A1 Fig. 118 Active TB patients inclusion Criteria As above Clinica review & 9 months Pre-treatment Sample Corenced arti treatient 2 weeks. Sample 2 months sample 4 months sample 6 months sample Š ŠSŠŠs Š Y SSSS Š SSSSSSSS SSSSSSSSSSSS: x S. Š Patent Application Publication May 14, 2015 Sheet 37 of 66 US 201S/O133469 A1 Patent Application Publication May 14, 2015 Sheet 38 of 66 US 201S/O133469 A1 Fig. 2C 393 sigrature 86 signature s:::: Fig. 13A Sagit Africa: 2Gi Cohort, gees pierraised to 8diar; i383: ::::::::::::: 88::::::: Patent Application Publication May 14, 2015 Sheet 39 of 66 US 201S/O133469 A1 \f"|8+3A?IOV/8||N3 (1s1)izg9)quoqoOTIOZpo?u/v/unnos peneaunun,unuz?,9,z,xwpeneau-aud Patent Application Publication May 14, 2015 Sheet 40 of 66 US 201S/O133469 A1 Fig.
Load more

Recommended publications
  • Longitudinal Peripheral Blood Transcriptional Analysis of COVID-19 Patients
    medRxiv preprint doi: https://doi.org/10.1101/2020.05.05.20091355; this version posted May 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. 1 Longitudinal peripheral blood transcriptional analysis of COVID-19 patients 2 captures disease progression and reveals potential biomarkers 3 Qihong Yan1,5,†, Pingchao Li1,†, Xianmiao Ye1,†, Xiaohan Huang1,5,†, Xiaoneng Mo2, 4 Qian Wang1, Yudi Zhang1, Kun Luo1, Zhaoming Chen1, Jia Luo1, Xuefeng Niu3, Ying 5 Feng3, Tianxing Ji3, Bo Feng3, Jinlin Wang2, Feng Li2, Fuchun Zhang2, Fang Li2, 6 Jianhua Wang1, Liqiang Feng1, Zhilong Chen4,*, Chunliang Lei2,*, Linbing Qu1,*, Ling 7 Chen1,2,3,4,* 8 1Guangzhou Regenerative Medicine and Health-Guangdong Laboratory 9 (GRMH-GDL), Guangdong Laboratory of Computational Biomedicine, Guangzhou 10 Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 11 China 12 2Guangzhou Institute of Infectious Disease, Guangzhou Eighth People’s Hospital, 13 Guangzhou Medical University, Guangzhou, China 14 3State Key Laboratory of Respiratory Disease, National Clinical Research Center for 15 Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated 16 Hospital of Guangzhou Medical University, Guangzhou, China 17 4School of Medicine, Huaqiao University, Xiamen, China 18 5University of Chinese Academy of Science, Beijing, China 19 †These authors contributed equally to this work. 20 *To whom correspondence should be addressed: Ling Chen ([email protected]), 21 Linbing Qu ([email protected]), Chunliang Lei ([email protected]), Zhilong 22 Chen ([email protected]) NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • Apoptotic Cells Inflammasome Activity During the Uptake of Macrophage
    Downloaded from http://www.jimmunol.org/ by guest on September 29, 2021 is online at: average * The Journal of Immunology , 26 of which you can access for free at: 2012; 188:5682-5693; Prepublished online 20 from submission to initial decision 4 weeks from acceptance to publication April 2012; doi: 10.4049/jimmunol.1103760 http://www.jimmunol.org/content/188/11/5682 Complement Protein C1q Directs Macrophage Polarization and Limits Inflammasome Activity during the Uptake of Apoptotic Cells Marie E. Benoit, Elizabeth V. Clarke, Pedro Morgado, Deborah A. Fraser and Andrea J. Tenner J Immunol cites 56 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription http://www.jimmunol.org/content/suppl/2012/04/20/jimmunol.110376 0.DC1 This article http://www.jimmunol.org/content/188/11/5682.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 29, 2021. The Journal of Immunology Complement Protein C1q Directs Macrophage Polarization and Limits Inflammasome Activity during the Uptake of Apoptotic Cells Marie E.
    [Show full text]
  • Common Differentially Expressed Genes and Pathways Correlating Both Coronary Artery Disease and Atrial Fibrillation
    EXCLI Journal 2021;20:126-141– ISSN 1611-2156 Received: December 08, 2020, accepted: January 11, 2021, published: January 18, 2021 Supplementary material to: Original article: COMMON DIFFERENTIALLY EXPRESSED GENES AND PATHWAYS CORRELATING BOTH CORONARY ARTERY DISEASE AND ATRIAL FIBRILLATION Youjing Zheng, Jia-Qiang He* Department of Biomedical Sciences and Pathobiology, College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA * Corresponding author: Jia-Qiang He, Department of Biomedical Sciences and Pathobiology, Virginia Tech, Phase II, Room 252B, Blacksburg, VA 24061, USA. Tel: 1-540-231-2032. E-mail: [email protected] https://orcid.org/0000-0002-4825-7046 Youjing Zheng https://orcid.org/0000-0002-0640-5960 Jia-Qiang He http://dx.doi.org/10.17179/excli2020-3262 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/). Supplemental Table 1: Abbreviations used in the paper Abbreviation Full name ABCA5 ATP binding cassette subfamily A member 5 ABCB6 ATP binding cassette subfamily B member 6 (Langereis blood group) ABCB9 ATP binding cassette subfamily B member 9 ABCC10 ATP binding cassette subfamily C member 10 ABCC13 ATP binding cassette subfamily C member 13 (pseudogene) ABCC5 ATP binding cassette subfamily C member 5 ABCD3 ATP binding cassette subfamily D member 3 ABCE1 ATP binding cassette subfamily E member 1 ABCG1 ATP binding cassette subfamily G member 1 ABCG4 ATP binding cassette subfamily G member 4 ABHD18 Abhydrolase domain
    [Show full text]
  • Interactions Between APOBEC3 and Murine Retroviruses: Mechanisms of Restriction and Drug Resistance
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2013 Interactions Between APOBEC3 and Murine Retroviruses: Mechanisms of Restriction and Drug Resistance Alyssa Lea MacMillan University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Virology Commons Recommended Citation MacMillan, Alyssa Lea, "Interactions Between APOBEC3 and Murine Retroviruses: Mechanisms of Restriction and Drug Resistance" (2013). Publicly Accessible Penn Dissertations. 894. https://repository.upenn.edu/edissertations/894 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/894 For more information, please contact [email protected]. Interactions Between APOBEC3 and Murine Retroviruses: Mechanisms of Restriction and Drug Resistance Abstract APOBEC3 proteins are important for antiretroviral defense in mammals. The activity of these factors has been well characterized in vitro, identifying cytidine deamination as an active source of viral restriction leading to hypermutation of viral DNA synthesized during reverse transcription. These mutations can result in viral lethality via disruption of critical genes, but in some cases is insufficiento t completely obstruct viral replication. This sublethal level of mutagenesis could aid in viral evolution. A cytidine deaminase-independent mechanism of restriction has also been identified, as catalytically inactive proteins are still able to inhibit infection in vitro. Murine retroviruses do not exhibit characteristics of hypermutation by mouse APOBEC3 in vivo. However, human APOBEC3G protein expressed in transgenic mice maintains antiviral restriction and actively deaminates viral genomes. The mechanism by which endogenous APOBEC3 proteins function is unclear. The mouse provides a system amenable to studying the interaction of APOBEC3 and retroviral targets in vivo.
    [Show full text]
  • Supplementary Information.Pdf
    Supplementary Information Whole transcriptome profiling reveals major cell types in the cellular immune response against acute and chronic active Epstein‐Barr virus infection Huaqing Zhong1, Xinran Hu2, Andrew B. Janowski2, Gregory A. Storch2, Liyun Su1, Lingfeng Cao1, Jinsheng Yu3, and Jin Xu1 Department of Clinical Laboratory1, Children's Hospital of Fudan University, Minhang District, Shanghai 201102, China; Departments of Pediatrics2 and Genetics3, Washington University School of Medicine, Saint Louis, Missouri 63110, United States. Supplementary information includes the following: 1. Supplementary Figure S1: Fold‐change and correlation data for hyperactive and hypoactive genes. 2. Supplementary Table S1: Clinical data and EBV lab results for 110 study subjects. 3. Supplementary Table S2: Differentially expressed genes between AIM vs. Healthy controls. 4. Supplementary Table S3: Differentially expressed genes between CAEBV vs. Healthy controls. 5. Supplementary Table S4: Fold‐change data for 303 immune mediators. 6. Supplementary Table S5: Primers used in qPCR assays. Supplementary Figure S1. Fold‐change (a) and Pearson correlation data (b) for 10 cell markers and 61 hypoactive and hyperactive genes identified in subjects with acute EBV infection (AIM) in the primary cohort. Note: 23 up‐regulated hyperactive genes were highly correlated positively with cytotoxic T cell (Tc) marker CD8A and NK cell marker CD94 (KLRD1), and 38 down‐regulated hypoactive genes were highly correlated positively with B cell, conventional dendritic cell
    [Show full text]
  • Supplemental Table S1. Primers for Sybrgreen Quantitative RT-PCR Assays
    Supplemental Table S1. Primers for SYBRGreen quantitative RT-PCR assays. Gene Accession Primer Sequence Length Start Stop Tm GC% GAPDH NM_002046.3 GAPDH F TCCTGTTCGACAGTCAGCCGCA 22 39 60 60.43 59.09 GAPDH R GCGCCCAATACGACCAAATCCGT 23 150 128 60.12 56.52 Exon junction 131/132 (reverse primer) on template NM_002046.3 DNAH6 NM_001370.1 DNAH6 F GGGCCTGGTGCTGCTTTGATGA 22 4690 4711 59.66 59.09% DNAH6 R TAGAGAGCTTTGCCGCTTTGGCG 23 4797 4775 60.06 56.52% Exon junction 4790/4791 (reverse primer) on template NM_001370.1 DNAH7 NM_018897.2 DNAH7 F TGCTGCATGAGCGGGCGATTA 21 9973 9993 59.25 57.14% DNAH7 R AGGAAGCCATGTACAAAGGTTGGCA 25 10073 10049 58.85 48.00% Exon junction 9989/9990 (forward primer) on template NM_018897.2 DNAI1 NM_012144.2 DNAI1 F AACAGATGTGCCTGCAGCTGGG 22 673 694 59.67 59.09 DNAI1 R TCTCGATCCCGGACAGGGTTGT 22 822 801 59.07 59.09 Exon junction 814/815 (reverse primer) on template NM_012144.2 RPGRIP1L NM_015272.2 RPGRIP1L F TCCCAAGGTTTCACAAGAAGGCAGT 25 3118 3142 58.5 48.00% RPGRIP1L R TGCCAAGCTTTGTTCTGCAAGCTGA 25 3238 3214 60.06 48.00% Exon junction 3124/3125 (forward primer) on template NM_015272.2 Supplemental Table S2. Transcripts that differentiate IPF/UIP from controls at 5%FDR Fold- p-value Change Transcript Gene p-value p-value p-value (IPF/UIP (IPF/UIP Cluster ID RefSeq Symbol gene_assignment (Age) (Gender) (Smoking) vs. C) vs. C) NM_001178008 // CBS // cystathionine-beta- 8070632 NM_001178008 CBS synthase // 21q22.3 // 875 /// NM_0000 0.456642 0.314761 0.418564 4.83E-36 -2.23 NM_003013 // SFRP2 // secreted frizzled- 8103254 NM_003013
    [Show full text]
  • Molecular Signatures Differentiate Immune States in Type 1 Diabetes Families
    Page 1 of 65 Diabetes Molecular signatures differentiate immune states in Type 1 diabetes families Yi-Guang Chen1, Susanne M. Cabrera1, Shuang Jia1, Mary L. Kaldunski1, Joanna Kramer1, Sami Cheong2, Rhonda Geoffrey1, Mark F. Roethle1, Jeffrey E. Woodliff3, Carla J. Greenbaum4, Xujing Wang5, and Martin J. Hessner1 1The Max McGee National Research Center for Juvenile Diabetes, Children's Research Institute of Children's Hospital of Wisconsin, and Department of Pediatrics at the Medical College of Wisconsin Milwaukee, WI 53226, USA. 2The Department of Mathematical Sciences, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, USA. 3Flow Cytometry & Cell Separation Facility, Bindley Bioscience Center, Purdue University, West Lafayette, IN 47907, USA. 4Diabetes Research Program, Benaroya Research Institute, Seattle, WA, 98101, USA. 5Systems Biology Center, the National Heart, Lung, and Blood Institute, the National Institutes of Health, Bethesda, MD 20824, USA. Corresponding author: Martin J. Hessner, Ph.D., The Department of Pediatrics, The Medical College of Wisconsin, Milwaukee, WI 53226, USA Tel: 011-1-414-955-4496; Fax: 011-1-414-955-6663; E-mail: [email protected]. Running title: Innate Inflammation in T1D Families Word count: 3999 Number of Tables: 1 Number of Figures: 7 1 For Peer Review Only Diabetes Publish Ahead of Print, published online April 23, 2014 Diabetes Page 2 of 65 ABSTRACT Mechanisms associated with Type 1 diabetes (T1D) development remain incompletely defined. Employing a sensitive array-based bioassay where patient plasma is used to induce transcriptional responses in healthy leukocytes, we previously reported disease-specific, partially IL-1 dependent, signatures associated with pre and recent onset (RO) T1D relative to unrelated healthy controls (uHC).
    [Show full text]
  • Implications of Endogenous Retroelements in the Etiopatho- Genesis of Systemic Lupus Erythematosus
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 4 January 2021 Review Implications of Endogenous Retroelements in the Etiopatho- genesis of Systemic Lupus Erythematosus Kennedy C. Ukadike 1 and Tomas Mustelin 2,* 1 Division of Rheumatology, Department of Medicine, University of Washington School of Medicine, 750 Republican Street, Seattle, WA 98109; [email protected] 2 Division of Rheumatology, Department of Medicine, University of Washington School of Medicine, 750 Republican Street, Seattle, WA 98109; [email protected] * Correspondence: [email protected]; Tel.: +1 (206) 313-6130 Abstract: Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disease. While its eti- ology remains elusive, current understanding suggests a multifactorial process with contributions by genetic, immunologic, hormonal, and environmental factors. A hypothesis that combines several of these factors proposes that genomic elements, the L1 retrotransposons, are instrumental in SLE pathogenesis. L1 retroelements are transcriptionally activated in SLE and produce two proteins, ORF1p and ORF2p, which are immunogenic and can drive type I interferon (IFN) production by producing DNA species that activate cytosolic DNA sensors. In addition, these two proteins reside in RNA-rich macromolecular assemblies that also contain well-known SLE autoantigens like Ro60. We surmise that cells expressing L1 will exhibit all the hallmarks of cells infected by a virus, result- ing in a cellular and humoral immune response similar to those in chronic viral infections. However, unlike exogenous viruses, L1 retroelements cannot be eliminated from the host genome. Hence, dysregulated L1 will cause a chronic, but perhaps episodic, challenge for the immune system. The clinical and immunological features of SLE can be largely explained by this model.
    [Show full text]
  • Deaminase-Independent Mode of Antiretroviral Action in Human and Mouse APOBEC3 Proteins
    microorganisms Review Deaminase-Independent Mode of Antiretroviral Action in Human and Mouse APOBEC3 Proteins Yoshiyuki Hakata 1,* and Masaaki Miyazawa 1,2 1 Department of Immunology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan; [email protected] 2 Kindai University Anti-Aging Center, 3-4-1 Kowakae, Higashiosaka, Osaka 577-8502, Japan * Correspondence: [email protected]; Tel.: +81-72-367-7660 Received: 8 December 2020; Accepted: 9 December 2020; Published: 12 December 2020 Abstract: Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3 (APOBEC3) proteins (APOBEC3s) are deaminases that convert cytosines to uracils predominantly on a single-stranded DNA, and function as intrinsic restriction factors in the innate immune system to suppress replication of viruses (including retroviruses) and movement of retrotransposons. Enzymatic activity is supposed to be essential for the APOBEC3 antiviral function. However, it is not the only way that APOBEC3s exert their biological function. Since the discovery of human APOBEC3G as a restriction factor for HIV-1, the deaminase-independent mode of action has been observed. At present, it is apparent that both the deaminase-dependent and -independent pathways are tightly involved not only in combating viruses but also in human tumorigenesis. Although the deaminase-dependent pathway has been extensively characterized so far, understanding of the deaminase-independent pathway remains immature. Here, we review existing knowledge regarding the deaminase-independent antiretroviral functions of APOBEC3s and their molecular mechanisms. We also discuss the possible unidentified molecular mechanism for the deaminase-independent antiretroviral function mediated by mouse APOBEC3. Keywords: APOBEC3; deaminase-independent antiretroviral function; innate immunity 1.
    [Show full text]
  • 1 APOBEC-Mediated Mutagenesis in Urothelial Carcinoma Is Associated
    bioRxiv preprint doi: https://doi.org/10.1101/123802; this version posted April 4, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response Alexander P. Glaser MD, Damiano Fantini PhD, Kalen J. Rimar MD, Joshua J. Meeks MD PhD APG, DF, KJR, JJM: Northwestern University, Department of Urology, Chicago, IL, 60607 Running title: APOBEC mutagenesis in bladder cancer *Corresponding author: Joshua J. Meeks, MD PhD 303 E. Chicago Ave. Tarry 16-703 Chicago, IL 60611 Email: [email protected] Keywords (4-6): • Urinary bladder neoplasms • APOBEC Deaminases • Mutagenesis • DNA damage • Interferon Abbreviations and Acronyms: TCGA – The Cancer Genome Atlas ssDNA – single stranded DNA APOBEC –apolipoprotein B mRNA editing catalytic polypeptide-like GCAC – Genome Data Analysis Center MAF – mutation annotation format “APOBEC-high” – tumors enriched for APOBEC mutagenesis “APOBEC-low” – tumors not enriched for APOBEC mutagenesis 1 bioRxiv preprint doi: https://doi.org/10.1101/123802; this version posted April 4, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract: Background: The APOBEC family of enzymes is responsible for a mutation signature characterized by a TCW>T/G mutation. APOBEC-mediated mutagenesis is implicated in a wide variety of tumors, including bladder cancer. In this study, we explore the APOBEC mutational signature in bladder cancer and the relationship with specific mutations, molecular subtype, gene expression, and survival.
    [Show full text]
  • ©Ferrata Storti Foundation
    Original Articles T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response Peter Van Loo,1,2,3 Thomas Tousseyn,4 Vera Vanhentenrijk,4 Daan Dierickx,5 Agnieszka Malecka,6 Isabelle Vanden Bempt,4 Gregor Verhoef,5 Jan Delabie,6 Peter Marynen,1,2 Patrick Matthys,7 and Chris De Wolf-Peeters4 1Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium; 2Department of Human Genetics, K.U.Leuven, Leuven, Belgium; 3Bioinformatics Group, Department of Electrical Engineering, K.U.Leuven, Leuven, Belgium; 4Department of Pathology, University Hospitals K.U.Leuven, Leuven, Belgium; 5Department of Hematology, University Hospitals K.U.Leuven, Leuven, Belgium; 6Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway, and 7Department of Microbiology and Immunology, Rega Institute for Medical Research, K.U.Leuven, Leuven, Belgium Citation: Van Loo P, Tousseyn T, Vanhentenrijk V, Dierickx D, Malecka A, Vanden Bempt I, Verhoef G, Delabie J, Marynen P, Matthys P, and De Wolf-Peeters C. T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolero- genic host immune response. Haematologica. 2010;95:440-448. doi:10.3324/haematol.2009.009647 The Online Supplementary Tables S1-5 are in separate PDF files Supplementary Design and Methods One microgram of total RNA was reverse transcribed using random primers and SuperScript II (Invitrogen, Merelbeke, Validation of microarray results by real-time quantitative Belgium), as recommended by the manufacturer. Relative reverse transcriptase polymerase chain reaction quantification was subsequently performed using the compar- Ten genes measured by microarray gene expression profil- ative CT method (see User Bulletin #2: Relative Quantitation ing were validated by real-time quantitative reverse transcrip- of Gene Expression, Applied Biosystems).
    [Show full text]
  • Quantification of Ongoing APOBEC3A Activity in Tumor Cells by Monitoring
    ARTICLE https://doi.org/10.1038/s41467-020-16802-8 OPEN Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots Pégah Jalili 1, Danae Bowen 1, Adam Langenbucher2, Shinho Park 1, Kevin Aguirre 1, ✉ ✉ Ryan B. Corcoran 2, Angela G. Fleischman 3, Michael S. Lawrence 2,4,5 , Lee Zou 2,4 & ✉ Rémi Buisson 1,2 APOBEC3A is a cytidine deaminase driving mutagenesis, DNA replication stress and DNA 1234567890():,; damage in cancer cells. While the APOBEC3A-induced vulnerability of cancers offers an opportunity for therapy, APOBEC3A protein and mRNA are difficult to quantify in tumors due to their low abundance. Here, we describe a quantitative and sensitive assay to measure the ongoing activity of APOBEC3A in tumors. Using hotspot RNA mutations identified from APOBEC3A-positive tumors and droplet digital PCR, we develop an assay to quantify the RNA-editing activity of APOBEC3A. This assay is superior to APOBEC3A protein- and mRNA-based assays in predicting the activity of APOBEC3A on DNA. Importantly, we demonstrate that the RNA mutation-based APOBEC3A assay is applicable to clinical samples from cancer patients. Our study presents a strategy to follow the dysregulation of APOBEC3A in tumors, providing opportunities to investigate the role of APOBEC3A in tumor evolution and to target the APOBEC3A-induced vulnerability in therapy. 1 Department of Biological Chemistry, Center for Epigenetics and Metabolism, Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA. 2 Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. 3 Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA.
    [Show full text]